Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial

NCT01667263 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT01667263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01667263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2012
Completion date
February 1, 2017
Enrollment
130 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune thrombocytopenia